YD Bio Ltd (YDES): Operating Cash Flow

Annual figures by period end, from SEC filings.

-$6.60M

Year ended 2025-12-31

2023-12-31 Operating Cash Flow (USD) 2025-12-31

Period ended	Operating Cash Flow	Change YoY	Source filing
2025-12-31	-$6.60M	n/m	2026-04-30, From 2025-01-01
2024-12-31	-$1.22M	n/m	2026-04-30, From 2024-01-01
2023-12-31	-$55.7K	n/a	2026-04-30, From 2023-01-01

Operating Cash Flow at similar companies

Companies with the same SEC industry code (Services-Medical Laboratories), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	Operating Cash Flow	Change YoY
YD Bio Ltd (YDES)	2025-12-31	-$6.60M	n/m
Sera Prognostics, Inc. (SERA)	2025-12-31	-$25.62M	n/m
Aclarion, Inc. (ACON)	2025-12-31	-$7.16M	n/m
BioNexus Gene Lab Corp (BGLC)	2025-12-31	-$1.84M	n/m
American Shared Hospital Services (AMS)	2025-12-31	$3.10M	n/m
CapForce Inc. (CFOR)	2025-12-31	-$1.18M	n/m
Exagen Inc. (XGN)	2025-12-31	-$13.62M	n/m
Personalis, Inc. (PSNL)	2025-12-31	-$74.95M	n/m
Biodesix Inc (BDSX)	2025-12-31	-$23.27M	n/m

Compare YDES, SERA, ACON, BGLC side by side · Screen every company in Services-Medical Laboratories ↗